{
  "extraction_date": "2025-12-23",
  "condition": "AUTISM_SPECTRUM_DISORDER",
  "phase": "4",
  "priority": "Phase 4 - Emerging Indications Expansion",
  "total_studies": 17,
  "studies": [
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_001",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "The endocannabinoid system and autism spectrum disorders: Insights from animal models",
      "citation": "Zamberletti et al. 2017. International Journal of Molecular Sciences 18: 1916.",
      "publication_year": 2017,
      "journal": "International Journal of Molecular Sciences",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_002",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Lower circulating endocannabinoid levels in children with autism spectrum disorder",
      "citation": "Aran et al. 2019. Molecular Autism 10.",
      "publication_year": 2019,
      "journal": "Molecular Autism",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_003",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Cannabis and cannabinoid use in autism spectrum disorder: A systematic review",
      "citation": "da Silva et al. 2021. Trends in Psychiatry and Psychotherapy.",
      "publication_year": 2021,
      "journal": "Trends in Psychiatry and Psychotherapy",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_004",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use",
      "citation": "Fleury-Teixeira et al. 2019. Frontiers in Neurology 10.",
      "publication_year": 2019,
      "journal": "Frontiers in Neurology",
      "intervention": {
        "cannabis_type": "CBD-enriched extract",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": 18,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_005",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Cannabidiol-based medical cannabis in children with autism: A retrospective feasibility study",
      "citation": "Aran et al. 2018. Neurology 90.",
      "publication_year": 2018,
      "journal": "Neurology",
      "intervention": {
        "cannabis_type": "CBD-dominant cannabis extract",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_006",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Real life experiences of medical cannabis treatment in autism: Analysis of safety and efficacy",
      "citation": "Bar-Lev Schleider et al. 2019. Scientific Reports 9: 200.",
      "publication_year": 2019,
      "journal": "Scientific Reports",
      "intervention": {
        "cannabis_type": "Medical cannabis",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_007",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Oral cannabidiol use in children in with autism spectrum disorder to treat related symptoms and co-morbidities",
      "citation": "Barchel et al. 2019. Frontiers in Pharmacology 9: 1521.",
      "publication_year": 2019,
      "journal": "Frontiers in Pharmacology",
      "intervention": {
        "cannabis_type": "Oral cannabidiol",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "oral",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_008",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Autism spectrum disorder and medical cannabis: Review and clinical experience",
      "citation": "Mostafavi and Gaitanis. 2020. Seminars in Pediatric Neurology 35.",
      "publication_year": 2020,
      "journal": "Seminars in Pediatric Neurology",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_CASE_SERIES_001",
      "study_type": "case_series",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report",
      "citation": "Andrea-Ponton et al. 2021. Journal of Medical Case Reports.",
      "publication_year": 2021,
      "journal": "Journal of Medical Case Reports",
      "intervention": {
        "cannabis_type": "Cannabinoid extract",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": 1,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_OBSERVATIONAL_009",
      "study_type": "observational",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "CBD-enriched cannabis for autism spectrum disorder: An experience of a single center in Turkey and reviews of the literature",
      "citation": "Bilge and Ekici. 2021. Journal of Cannabis Research.",
      "publication_year": 2021,
      "journal": "Journal of Cannabis Research",
      "intervention": {
        "cannabis_type": "CBD-enriched cannabis",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "Turkey",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_RCT_001",
      "study_type": "RCT",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Cannabinoid treatment for autism: A proof-of-concept randomized trials",
      "citation": "Aran et al. 2021. Molecular Autism 12.",
      "publication_year": 2021,
      "journal": "Molecular Autism",
      "intervention": {
        "cannabis_type": "Cannabinoid treatment",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "AUTISM_SPECTRUM_DISORDER_RCT_002",
      "study_type": "RCT",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: Randomized, double-blind and controlled placebo clinical trial",
      "citation": "da Silva Junior et al. 2022. Trends in Psychiatry and Psychotherapy.",
      "publication_year": 2022,
      "journal": "Trends in Psychiatry and Psychotherapy",
      "intervention": {
        "cannabis_type": "Cannabidiol-rich cannabis extract",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "Brazil",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML autism spectrum disorder research library (references section)."
    },
    {
      "study_id": "CT_NCT02956226",
      "study_type": "RCT",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "Cannabinoids for Behavioral Problems in Children With ASD",
      "citation": "ClinicalTrials.gov NCTNCT02956226",
      "publication_year": 2018,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabinoids - 99% pure cannabinoids mix, Cannabinoids - whole plant extract",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition.",
          "Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition."
        ],
        "outcome_measures": [
          "Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition.",
          "Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02956226",
        "enrollment": 150,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02956226"
      }
    },
    {
      "study_id": "CT_NCT05212493",
      "study_type": "RCT",
      "condition": "AUTISM_SPECTRUM_DISORDER",
      "study_title": "The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder",
      "citation": "ClinicalTrials.gov NCTNCT05212493",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis oil",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Cannabinoids levels change",
          "Changes in attention span",
          "Changes in cognitive level",
          "Comparison of efficacy between two different cannabis oil products",
          "Changes in adaptive behavior",
          "Changes in violent behavior"
        ],
        "outcome_measures": [
          "Cannabinoids levels change",
          "Changes in attention span",
          "Changes in cognitive level",
          "Comparison of efficacy between two different cannabis oil products",
          "Changes in adaptive behavior",
          "Changes in violent behavior"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05212493",
        "enrollment": 128,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05212493"
      }
    },
    {
      "study_id": "CT_NCT03886753",
      "study_type": "Clinical Trial",
      "condition": "AUTISM",
      "study_title": "Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products",
      "citation": "ClinicalTrials.gov NCTNCT03886753",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in symptoms"
        ],
        "outcome_measures": [
          "Change in symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03886753",
        "enrollment": 10,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03886753"
      }
    },
    {
      "study_id": "CT_NCT03677089",
      "study_type": "RCT",
      "condition": "AUTISM",
      "study_title": "Extension for Community Healthcare Outcomes Autism Replication Evaluation",
      "citation": "ClinicalTrials.gov NCTNCT03677089",
      "publication_year": 2018,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Longitudinal Pattern of ASD Screening in PCP Charts",
          "Longitudinal Pattern of Reported Co-occurring Medical Conditions Correctly Treated in PCP Charts"
        ],
        "outcome_measures": [
          "Longitudinal Pattern of ASD Screening in PCP Charts",
          "Longitudinal Pattern of Reported Co-occurring Medical Conditions Correctly Treated in PCP Charts"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03677089",
        "enrollment": 148,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03677089"
      }
    },
    {
      "study_id": "CT_NCT05302167",
      "study_type": "RCT",
      "condition": "AUTISM",
      "study_title": "Molehill Mountain Feasibility Study.",
      "citation": "ClinicalTrials.gov NCTNCT05302167",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)",
          "App acceptability/ feasibility survey"
        ],
        "outcome_measures": [
          "Change in 7-item Generalised Anxiety Disorder Scale (GAD-7)",
          "App acceptability/ feasibility survey"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05302167",
        "enrollment": 100,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05302167"
      }
    }
  ],
  "expansion_metadata": {
    "last_expanded": null,
    "total_expanded": 3
  }
}